EGFR-mutated NSCLC to SCLC transformation has been reported to occur in 3–15% of all EGFR-mutated patients, which suggests an overall incidence of 1% to 4.5% of all NSCLC cases, which underscores the rarity of this phenomenon that has been linked with resistance to EGFR TKI therapy [6,7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.